ERBB2 and glioblastoma: An independent randomized double-blind phase II trial involving a larger cohort of glioblastoma patients led to comparable conclusions using autologous DCs pulsed with six synthetic peptide epitopes derived from glioblastoma-associated antigens MAGE-1, IL13Rα2, AIM-2, TRP-2, gp100, and HER-2 [118].